Some project and brand teams make a critical mistake early in their drugs’ development lifecycles - they fail to adequately prepare the market for their products. Early-stage commercialization and market preparation deficiencies often are the result of insufficient funding rather than poor planning. Don’t allow your product’s commercial potential to falter. Use Early-Stage Pharmaceutical Marketing Budgets: Preparing for Product Launch to bolster your case for larger commercial budgets and to benchmark your marketing spends in pre-clinical development, Phase I and Phase II.

With spending data for the commercialization of 14 brands, this report analyzes early-phase resource allocation for products of all sizes - including niche products with modest budgets, mid-level products balancing their expenditures, and larger brands with blockbuster hopes. Each brand’s data are presented in product profile format. The profiles break down each brand’s commercialization budgets into 10 spending categories - providing our clients with more detailed budgets than were included in our competitors’ reports today. The commercialization spending categories featured in this report include the following :
 

• Thought leader development

• Thought leader programs

• Medical education

• Medical information

• Market research

• Competitive intelligence

• Pricing strategy and analysis

• Pharmacoeconomics

• Reimbursement

• Advertising and promotions
   

Additional Information

Companies Included in Report

Allergan
Almirall Prodesfarma
Genentech
Immtech Pharmaceuticals
Merck Serono Biopharmaceuticals
Neurochem
Pfizer
Proacta
Procter & Gamble Pharmaceuticals
SciClone Pharmaceuticals
Wyeth
 

Table of Contents :

Report metrics :

Each of the 14 brand profiles included in this report contain the following metrics and brand characteristics:

Commercialization Metrics

Total commercial spending for pre-clinical, Phase I and Phase II

Pre-clinical, Phase I and Phase II spending for each of the following marketing categories and sub-categories

Medical affairs

Thought leader development

Thought leader programs

Medical education

Medical information

Decision support

Market research

Competitive intelligence

Market access

Pricing strategy and analysis

Pharmacoeconomics

Reimbursement

Advertising and promotions

Brand Characteristics and Context

Actual or projected launch dates for the US, Europe and Asia/Japan markets

Global and US peak annual sales

Number of years after launch that the drug is expected to reach global and US peak annual sales

Whether the drug is a first-in-class product

Whether the drug is indicated for first-line treatment

Therapeutic area

Brand development timelines (in number of months) for pre-clinical, Phase I and Phase II